Advancements and Challenges in Peptide-Based Cancer Vaccination: A Multidisciplinary Perspective
Vaccines · 22.08.2024 · 12 (8) · 950
DOI: 10.3390/vaccines12080950 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Vaccines, online erschienen am 22.08.2024. Verfasst von Dequan Liu und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China. Die Arbeit wurde bisher 41-mal zitiert (Crossref) und nennt 227 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: the Horizontal Project Department Fund of the First Affiliated Hospital of Dalian Medical University, the Liaoning Provincial Education Department.
Abstract (Originalsprache)
With the continuous advancements in tumor immunotherapy, researchers are actively exploring new treatment methods. Peptide therapeutic cancer vaccines have garnered significant attention for their potential in improving patient outcomes. Despite its potential, only a single peptide-based cancer vaccine has been approved by the U.S. Food and Drug Administration (FDA). A comprehensive understanding of the underlying mechanisms and current development status is crucial for advancing these vaccines. This review provides an in-depth analysis of the production principles and therapeutic mechanisms of peptide-based cancer vaccines, highlights the commonly used peptide-based cancer vaccines, and examines the synergistic effects of combining these vaccines with immunotherapy, targeted therapy, radiotherapy, and chemotherapy. While some studies have yielded suboptimal results, the potential of combination therapies remains substantial. Additionally, we addressed the management and adverse events associated with peptide-based cancer vaccines, noting their relatively higher safety profile compared to traditional radiotherapy and chemotherapy. Lastly, we also discussed the roles of adjuvants and targeted delivery systems in enhancing vaccine efficacy. In conclusion, this review comprehensively outlines the current landscape of peptide-based cancer vaccination and underscores its potential as a pivotal immunotherapy approach.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Urology, The First Affiliated Hospital of Dalian Medical University, Dalian 116011, China.
- Department of Stomatology, General Hospital of Northern Theater Command, Shenyang 110016, China.
ORCID-Profile: Dequan Liu, Shijin Wang, Xiangyu Che
Förderung
- the Horizontal Project Department Fund of the First Affiliated Hospital of Dalian Medical University
- the Liaoning Provincial Education Department
Zitieren
APA
Liu, D., Liu, L., Li, X., Wang, S., Wu, G., & Che, X. (2024). Advancements and Challenges in Peptide-Based Cancer Vaccination: A Multidisciplinary Perspective. Vaccines, 12(8), 950. https://doi.org/10.3390/vaccines12080950
Vancouver
Liu D, Liu L, Li X, Wang S, Wu G, Che X. Advancements and Challenges in Peptide-Based Cancer Vaccination: A Multidisciplinary Perspective. Vaccines. 2024;12(8):950. doi:10.3390/vaccines12080950
BibTeX
@article{Liu2024,
author = {Liu, Dequan and Liu, Lei and Li, Xinghan and Wang, Shijin and Wu, Guangzhen and Che, Xiangyu},
title = {Advancements and Challenges in Peptide-Based Cancer Vaccination: A Multidisciplinary Perspective},
journal = {Vaccines},
year = {2024},
volume = {12},
number = {8},
pages = {950},
doi = {10.3390/vaccines12080950}
}
EUVIMED